Palisade Bio (PALI) Non-Current Debt (2013 - 2020)

Palisade Bio (PALI) reported Non-Current Debt of $94000.0 for Q4 2020, down 96.31% quarter-over-quarter from $2.5 million in Q1 2016.

Palisade Bio (PALI) Non-Current Debt (2013 - 2020) Analysis & Trends

Palisade Bio (PALI) has 5 years of Non-Current Debt data on file, last reported at $94000.0 in Q4 2020.

Non-Current Debt for Q4 2020 came in at $94000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $94000.0 (changed N/A YoY), and the FY2020 annual result was $94000.0, changed N/A from the prior year.
Non-Current Debt retreated to $94000.0 in Q4 2020 per PALI's latest filing, from $2.5 million in the prior quarter.
Over five years, Non-Current Debt peaked at $2.5 million in Q1 2016 and troughed at $94000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Palisade Bio	391.02 Mn	261.45 Mn	-	-

Download Data